secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2024-01-16T23:59:59+00:00
Accession:  0000950170-24-004616
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves CRISPR's CASGEVY for transfusion-dependent beta thalassemia in patients 12+
--------------------------------------------------------------------------------

- U.S. FDA approved CASGEVY (exagamglogene autotemcel) on Jan 16, 2024 for transfusion-dependent beta thalassemia in patients 12 years and older.
- CASGEVY is a CRISPR/Cas9 gene-edited cell therapy developed by CRISPR Therapeutics.
- The approval expands treatment options for patients with transfusion-dependent beta thalassemia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017024004616/0000950170-24-004616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017024004616/crsp-20240116.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-004616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer